Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with histologic confirmation of metastatic (stage IV) 'triple receptor-negative' breast cancer. Tissue must be available at baseline or agree to biopsy. The diagnosis of 'triple receptor-negative' breast cancer requires that either the primary tumor or a metastatic deposit be shown to be negative for estrogen receptors (ER) and progesterone receptors (PR) by immunohistochemistry (IHC) and for HER2/neu by IHC (i.e. a score of 0 and 1+) or fluorescent in situ hybridization (FISH).~2. EGFR protein expression and gene copy number will be evaluated on stored tissue sample at a later time. Unstained slides, a block, or agreement for biopsy is required for study participation.~3. Patients with metastatic breast cancer to any distant site are eligible once their disease is clinically/radiologically measurable~4. Patients must have disease which is resistant to taxanes and anthracyclines. There is no limit to the number of previous therapies for metastatic disease.~5. Patients are eligible if they have not had prior exposure to an EGFR inhibitor (e.g.Gefitinib, Erlotinib) or antibody (e.g. Cetuximab).~6. Availability of tissue blocks and/or fresh/frozen tumor samples is an eligibility requirement in order to run the EGFR IHC, FISH and to confirm, if needed ER, PR and HER2/neu status.~7. Patients may, but are not required, to have a repeat tumor biopsy performed on study entry prior to beginning therapy and also early during study therapy for correlative studies.~8. Patients with 'triple receptor-negative' metaplastic breast cancers are eligible if they meet the criterion of EGFR overexpression.~9. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy~10. Patients must have tissue blocks available from previous primary tumor surgery or biopsy or from a previous biopsy of metastatic disease for EGFR status assessment and for correlative studies~11. Patients should have adequate bone marrow function, as defined by peripheral granulocyte count of \>/= 1500/mm\^3, and a platelet count \>/= 100000/ mm\^3. Patients must have adequate liver function with a bilirubin within 1.5 times the upper limit of normal (ULN). Transaminases (SGPT) may be up to 5 \* the ULN and alkaline phosphatase may be up to 5 \* ULN~12. Patients should have adequate renal function (serum creatinine \</= 1.5 times the ULN)~13. Negative pregnancy test for a woman of childbearing potential~14. Women of childbearing potential must use a reliable and appropriate contraceptive method during the study~15. Patients with a performance status of 2 or better by World Health Organization (W.H.O.)~Exclusion Criteria:~1. Patients with uncompensated congestive cardiac failure are not eligible~2. Patients with a myocardial infarction in the previous 12 months are not eligible~3. Patients with central nervous system (CNS) metastases are not eligible~4. Patients with an organ allograft~5. Patients with a serious concurrent infection or illness including, but not limited to, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tarceva daily (Type: EXPERIMENTAL): Tarceva oral 150 mg daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).